Metronomic chemotherapy and nanocarrier platforms复制标题

节拍化疗和纳米载体平台

Chen and colleagues have explored the potential use of a nanoparticulate delivery system that can actively target tumor vasculature in metronomic chemotherapy. For achieving active tumor vasculature targeting, the surface of poly(lactic-co-glycolic acid)-based nanoparticles was decorated with a specific ligand moiety, SP5.2 peptide, a ligand for VEGFR-1 highly expressed on tumor vascular ECs [78], [79]. The anti-angiogenic/antitumor efficacy of the prepared SP5.2 peptide-conjugated nanoparticles encapsulating the cytotoxic drug DTX (SP5.2 DTX-NP) was challenged against a breast cancer xenograft tumor model using either MTD or metronomic dosing. Results revealed that metronomic SP5.2-DTX-NP exhibited potent antitumor activity, mainly via the anti-angiogenic potential of DTX, which was selectively delivered into tumor vascular endothelial cells via the interaction of SP5.2 peptide with the over-expression of VEGFR-1 on tumor vessels. In addition, targeted metronomic chemotherapy induced superior antitumor activity with minimal drug-associated toxicity, compared with treatment given in a maximum tolerated dose (MTD) regimen [74]. Later, the same research group [10] investigated the efficacy of a metronomic PTX using a tumor-vasculature targeted nanocarrier, which consisted of F56-conjugated PTX-loaded nanoparticles (F56-PTX-NP) in a breast cancer xenograft tumor model. F56 is a peptide ligand with high binding avidity to the VEGFR-1 highly expressed on tumor vascular ECs.

译文